Application of Quantitative Pharmacology in Development of Therapeutic Monoclonal Antibodies

被引：18
|
作者：
Tabrizi, Mohammad [1 ]
Funelas, Cherryl [2 ]
Suria, Hamza [3 ]
机构：
[1] AnaptysBio Inc, Preclin Dev, San Diego, CA 92121 USA
[2] Takeda San Francisco, Bioanalyt Dev, San Francisco, CA USA
[3] AnaptysBio Inc, Corp Dev, San Diego, CA 92121 USA
来源：
AAPS JOURNAL | 2010年 / 12卷 / 04期
关键词：
monoclonal antibodies; pharmacodynamics (PD); pharmacokinetics (PK); quantitative pharmacology; translational strategies; DEPENDENT CELLULAR CYTOTOXICITY; ENDOTHELIAL GROWTH-FACTOR; KAPPA-B LIGAND; POPULATION PHARMACOKINETICS; PHASE-I; RECEPTOR ACTIVATOR; MULTIPLE-MYELOMA; BONE METASTASES; CANCER-PATIENTS; HIGH-AFFINITY;
D O I：
10.1208/s12248-010-9220-2
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The advancement of therapeutic monoclonal antibodies during various stages of the drug development process can be effectively streamlined when appropriate translational strategies are applied. Design of successful translational strategies for development of monoclonal antibodies should allow for understanding of the dose- and concentration-response relationships with respect to both beneficial and toxic effects from early phases of drug development. Evaluation of relevant biomarkers during early stages of drug development should facilitate the successful design of safe and effective dosing strategies. Moreover, application of quantitative pharmacology is critical for translation of exposure-response relationships early on.
引用
收藏
页码：592 / 601
页数：10
相关论文
共 50 条
  • [1] Application of Quantitative Pharmacology in Development of Therapeutic Monoclonal Antibodies
    Mohammad Tabrizi
    Cherryl Funelas
    Hamza Suria
    The AAPS Journal, 2010, 12 : 592 - 601
  • [2] Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies: A Quantitative Pharmacology Framework
    Jason H. Williams
    Kai H. Liao
    Donghua Yin
    Xu Meng
    The AAPS Journal, 26
  • [3] Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies: A Quantitative Pharmacology Framework
    Williams, Jason H.
    Liao, Kai H.
    Yin, Donghua
    Meng, Xu
    AAPS JOURNAL, 2024, 26 (02):
  • [4] From the discovery of monoclonal antibodies to their therapeutic application: An historical reappraisal
    Ribatti, Domenico
    IMMUNOLOGY LETTERS, 2014, 161 (01) : 96 - 99
  • [5] Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma
    Allegra, Alessandro
    Penna, Giuseppa
    Alonci, Andrea
    Russo, Sabina
    Greve, Bruna
    Innao, Vanessa
    Minardi, Viviana
    Musolino, Caterina
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2013, 90 (06) : 441 - 468
  • [6] Therapeutic monoclonal antibodies in ophthalmology
    Rodrigues, Eduardo B.
    Farah, Michel E.
    Maia, Mauricio
    Penha, Fernando M.
    Regatieri, Caio
    Melo, Gustavo B.
    Pinheiro, Marcelo M.
    Zanetti, Carlos R.
    PROGRESS IN RETINAL AND EYE RESEARCH, 2009, 28 (02) : 117 - 144
  • [7] The challenges with developing therapeutic monoclonal antibodies for pandemic application
    Laustsen, Andreas H.
    Bohn, Markus-Frederik
    Ljungars, Anne
    EXPERT OPINION ON DRUG DISCOVERY, 2022, 17 (01) : 5 - 8
  • [8] Therapeutic application of monoclonal antibodies in cancer: advances and challenges
    Modjtahedi, Helmout
    Ali, Sumaira
    Essapen, Sharadah
    BRITISH MEDICAL BULLETIN, 2012, 104 (01) : 41 - 59
  • [9] Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
    Tabrizi, Mohammad
    Bornstein, Gadi Gazit
    Suria, Hamza
    AAPS JOURNAL, 2010, 12 (01): : 33 - 43
  • [10] 89Zr-PET Radiochemistry in the Development and Application of Therapeutic Monoclonal Antibodies and Other Biologicals
    Vugts, Danielle J.
    Visser, Gerard W. M.
    van Dongen, Guus A. M. S.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2013, 13 (04) : 446 - 457
12345